Daniel Bandari, MD, MS

Articles by Daniel Bandari, MD, MS

Key Points for the Management of Multiple Sclerosis

ByStephen Krieger, MD,Daniel Bandari, MD, MS,Bruce Hughes, MD,Mitzi Williams, MD,Heidi Crayton, MD

December 27th 2022

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, provide key takeaways for the treatment of patients with multiple sclerosis.

Updates on Vaccine Efficacy in Multiple Sclerosis

ByStephen Krieger, MD,Daniel Bandari, MD, MS,Bruce Hughes, MD,Mitzi Williams, MD,Heidi Crayton, MD

December 27th 2022

A panel of experts discuss COVID-19 vaccine efficacy for patients undergoing treatment for multiple sclerosis.

Discontinuation of Treatment for Pregnancy in Multiple Sclerosis

ByStephen Krieger, MD,Daniel Bandari, MD, MS,Bruce Hughes, MD,Mitzi Williams, MD,Heidi Crayton, MD

December 20th 2022

An expert panel considers patients with multiple sclerosis who may need to discontinue treatment during pregnancy.

Treatment Interruption and Cessation for Multiple Sclerosis

ByStephen Krieger, MD,Daniel Bandari, MD, MS,Bruce Hughes, MD,Mitzi Williams, MD,Heidi Crayton, MD

December 20th 2022

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, review data on short-term interruption of ponesimod vs teriflunomide when treating multiple sclerosis.

Switching Therapies for Patients with Multiple Sclerosis

ByStephen Krieger, MD,Daniel Bandari, MD, MS,Bruce Hughes, MD,Mitzi Williams, MD,Heidi Crayton, MD

December 13th 2022

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, discuss their approach to switching treatments for patients with multiple sclerosis and the timing between therapies.

Sequencing Disease-Modifying Therapies in Multiple Sclerosis

ByStephen Krieger, MD,Daniel Bandari, MD, MS,Bruce Hughes, MD,Mitzi Williams, MD,Heidi Crayton, MD

December 13th 2022

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, share their thoughts on sequencing disease-modifying therapies when treating patients with multiple sclerosis.

Long-Term Safety of S1P Receptor Modulators in Multiple Sclerosis

ByStephen Krieger, MD,Daniel Bandari, MD, MS,Bruce Hughes, MD,Mitzi Williams, MD,Heidi Crayton, MD

December 6th 2022

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, examine the safety of sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis.

Brain Health in Multiple Sclerosis

ByStephen Krieger, MD,Daniel Bandari, MD, MS,Bruce Hughes, MD,Mitzi Williams, MD,Heidi Crayton, MD

December 6th 2022

An expert panel talks about the preservation of brain health regarding the use of sphingosine 1-phosphate receptor modulators to treat multiple sclerosis.

S1P Receptor Modulator Treatment in Female Patients with MS

ByStephen Krieger, MD,Daniel Bandari, MD, MS,Bruce Hughes, MD,Mitzi Williams, MD,Heidi Crayton, MD

November 29th 2022

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, review data on ponesimod vs teriflunomide for the treatment of female patients with multiple sclerosis who are of childbearing age.

Overview of Sphingosine 1-Phosphate (S1P) Receptor Modulators

ByStephen Krieger, MD,Daniel Bandari, MD, MS,Bruce Hughes, MD,Mitzi Williams, MD,Heidi Crayton, MD

November 29th 2022

An expert panel provides an overview of sphingosine-1-phosphate receptor modulators and their use in the treatment of multiple sclerosis.

Differences Between MS Patient Characteristics in Clinical Trials and Real-World Populations

ByStephen Krieger, MD,Daniel Bandari, MD, MS,Bruce Hughes, MD,Mitzi Williams, MD,Heidi Crayton, MD

November 22nd 2022

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, review the OPTIMISE study and reflect on the differences between patient characteristics in clinical trial settings vs clinical practice.

Comorbidities in Patients With Multiple Sclerosis (MS)

ByStephen Krieger, MD,Daniel Bandari, MD, MS,Bruce Hughes, MD,Mitzi Williams, MD,Heidi Crayton, MD

November 22nd 2022

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, discuss the prevalence of comorbidities in patients with multiple sclerosis.